Spain · Delayed Price · Currency is EUR Grifols Earnings Call Transcripts
Fiscal Year 2025
-
Revenue and adjusted EBITDA grew strongly in 2025, with free cash flow and leverage targets exceeded. Strategic partnerships in Egypt and Canada, along with a focus on margin-accretive growth, position the company for continued deleveraging and profitability in 2026.
-
Q3 2025 saw strong revenue and EBITDA growth, led by immunoglobulins and biopharma, with improved free cash flow and leverage. Guidance for 2025 is reaffirmed, despite FX and IRA headwinds, and the pipeline remains robust with key launches on track.
-
H1 2025 saw robust revenue and EBITDA growth, margin expansion, and strong Free Cash Flow, driven by Biopharma and Diagnostics. Leverage hit a five-year low, dividend payments resumed, and guidance for 2025 was reaffirmed despite FX and pricing pressures.
-
Q1 2025 delivered record revenue, EBITDA, and free cash flow, with strong growth in biopharma and diagnostics. Guidance for 2025 is reaffirmed, supported by robust demand, operational efficiencies, and a resilient global supply chain, despite ongoing policy and macroeconomic uncertainties.
-
Management outlined a five-year plan to reach €10 billion revenue by 2029 and €14 billion by 2034, driven by biopharma growth, innovation, and operational efficiency. Margin expansion, disciplined capital allocation, and new product launches underpin the strategy, with dividends to resume in 2025.
Fiscal Year 2024
-
Record revenues and adjusted EBITDA were achieved in 2024, driven by strong Biopharma growth, robust demand for immunoglobulin and albumin, and operational efficiencies. Free cash flow and deleveraging exceeded expectations, with no major CapEx needed in the near term.
-
Q3 2024 saw double-digit revenue and EBITDA growth, improved free cash flow, and reduced leverage, driven by strong Biopharma and IG performance. Management remains confident in meeting full-year guidance, with continued focus on operational efficiency, innovation, and deleveraging.
-
Revenue grew 7.5% year-over-year in H1, with strong BioPharma and albumin performance, and adjusted EBITDA up 22%. Debt reduction advanced via Shanghai RAAS divestment, and full-year guidance for revenue, EBITDA, and positive free cash flow is reaffirmed.